6533b872fe1ef96bd12d393f
RESEARCH PRODUCT
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma
C. RobertP.a. AsciertoHelen GogasKeith T. FlahertyMichael D PickardGabriella LiszkayNaoya YamazakiIvana KrajsováC. DutriauxReinhard DummerRalf GutzmerClaus GarbeV. SandorJ.w.b. De GrootL.a. De ParsevalAna AranceMario MandalàDirk SchadendorfV. Chiarion SileniCarmen Loquaisubject
Oncologymedicine.medical_specialtybusiness.industryMelanomaMutantBinimetinibHematologymedicine.disease030226 pharmacology & pharmacyDermatology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOncologychemistryInternal medicineEncorafenibmedicinebusinessVemurafenib030217 neurology & neurosurgerymedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2017-09-01 | Annals of Oncology |